Everything below concerns LKKTETQ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
=== X-Ray Scattering === In 1953, Kaesberg and a few colleagues used x-ray scattering to determine the size and hydration of three different viruses: the southern bean mosaic virus, the tomato bushy stunt virus, and the tobacco necrosis virus. All three of the viruses had a sphere-like shape and internal hydration. They differed, however, in their diameters, with the tobacco necrosis virus having a diameter of 280 angstroms, the southern bean virus having a diameter of 286 angstroms, and the tomato bushy stunt virus having the largest diameter of them all: 309 angstroms. In 1954, Kaesberg and Paul Schmidt utilized small-angle X-ray scattering to measure the size of the yellow turnip mosaic virus and its associated protein. They found that both particles were almost spherical and the same size. They found that while the virus had a relatively constant electron density, the protein was a water-filled shell. In 1963, Margaret Wright and Paul Kaesberg used x-ray scattering to learn more about the inside of the bromegrass mosaic virus. They discovered that the virus had a 260 angstroms diameter and an inner region with an 80-angstrom diameter. Negatively stained bromegrass viruses had a slightly larger internal diameter, about 90 angstroms. They saw that the internal region was almost wholly empty and that the RNA and protein within the virus had almost equal electron densities. However, they noticed something different in the positively stained viruses. These viruses have nucleic acids compacted into a shell formation enveloped by proteins.
A study to test whether a new treatment has an effect (NCI) Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. (NLM) Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. (21CFR312) Phase II/III trial
=== North America === Soybeans were first introduced to North America from China in 1765, by Samuel Bowen, a former East India Company sailor who had visited China in conjunction with James Flint, the first Englishman legally permitted by the Chinese authorities to learn Chinese. The first "New World" soybean crop was grown on Skidaway Island, Georgia, in 1765 by Henry Yonge from seeds given him by Samuel Bowen. Bowen grew soy near Savannah, Georgia, possibly using funds from Flint, and made soy sauce for sale to England. Although soybean was introduced into North America in 1765, for the next 155 years, the crop was grown primarily for forage. In 1831, the first soy product "a few dozen India Soy" [sauce] arrived in Canada. Soybeans were probably first cultivated in Canada by 1855, and definitely in 1895 at Ontario Agricultural College. It was not until Lafayette Mendel and Thomas Burr Osborne showed that the nutritional value of soybean seeds could be increased by cooking, moisture or heat, that soy went from a farm animal feed to a human food. William Joseph Morse is considered the "father" of modern soybean agriculture in America. In 1910, he and Charles Piper began to popularize what was regarded as a relatively unknown Oriental peasant crop in America into a "golden bean", with the soybean becoming one of America's largest and most nutritious farm crops.
Sources: en.wikipedia.org
== Litigation == CLIA itself has not been the subject of much litigation. Federal district courts have held that the CLIA did not create a private cause of action for individuals to sue laboratories that do not comply with its provisions.
The adrenergic receptors were discovered Henry Hallett Dale in 1906 and the α- and β-adrenergic receptors were differentiated by Raymond P. Ahlquist in 1948. In 1967, the β-adrenergic receptors were further differentiated into the β1- and β2-adrenergic receptors by Alonzo M. Lands. The first beta blocker to be developed was dichloroisoprenaline, based on structural modification of the β-adrenergic receptor agonist isoprenaline (isoproterenol). It was described by C. E. Powell and I. H. Slater in 1958. However, dichloroisoprenaline had significant partial agonism and sympathomimetic activity and hence was not a pure antagonist. James Black and John Stephenson described pronethalol (nethalide; ICI-38,174; Alderlin) as a purely antagonistic beta blocker in 1962. But pronethalol suffered from off-target activity and associated side effects and toxicity. As such, it did not enter widespread use and was soon discontinued. In 1964, Black and colleagues published on propranolol (ICI-45,520; Inderal), which did not have the problems of earlier beta blockers. It was introduced for medical use under the brand name Inderal the same year and became the first widely used beta blocker. Since the introduction of propranolol, there have been three generations of beta blockers with different pharmacological properties, with numerous beta blockers having been developed and introduced for medical use.
Complicated intra-abdominal infections; Acute pyelonephritis; Complicated urinary tract infections. Hospital-acquired bacterial pneumonia and Ventilator-associated bacterial pneumonia (HABP/VABP) In addition, ceftolozane/tazobactam has demonstrated stability for administration by continuous infusion, including delivery via elastomeric pumps. This pharmacotechnical property supports its use in outpatient parenteral antimicrobial therapy (OPAT) programs, particularly for time-dependent β-lactam optimization and carbapenem-sparing strategies. In real-world OPAT cohorts, ceftolozane/tazobactam accounted for approximately 7.5% of antibiotics administered by continuous infusion.
=== Eligibility of minors === While the WPATH standards of care generally require the patient to have reached the age of medical majority, they include a separate section devoted to children and adolescents. Prepubescent children do not have access to medical intervention for gender-affirming therapy. After puberty, some medical intervention is available for adolescents depending on specific criteria for gender incongruence diagnosis, capacity for informed consent, and mental and physical health. According to a study by JAMA Pediatrics published in January 2025, less than 0.1% of adolescents covered by private medical insurance in the US take gender-affirming medication to treat gender dysphoria.
Sources: en.wikipedia.org
== GAR == Glycineamide ribonucleotide Glutathione amide reductase, an enzyme Grand Army of the Republic, US Civil War veterans organization; also Grand Army of the Republic (disambiguation) lists other organizations with that name Garrison Hall, University of Texas at Austin Great American Recreation, the company owned and operated Action Park in New Jersey, US until 1996 IOC code for artistic gymnastics at the Summer Olympics
According to Mediapart, the text was "mostly relayed by far-right activists, press outlets or personalities". Dora Moutot and Marguerite Stern later launched "femellism", a movement which according to Arrêt sur images is rejected by many feminists "for its transphobia". According to its report, the movement adheres to conspiracy theories about the "funding of the trans lobby" and remains close to ultraconservative and far-right ideology. The two activists rejected these accusations and characterized femellism as a fight "against the oppressions that women suffer because of their sex". Libération criticizes the two activists for ideological connections and common obsessions with the activists of La Manif pour tous and the far-right. Marguerite Stern later lent her support to a well-known figure of the far-right, Julien Rochedy, a masculinist and former national director of National Rally's youth group between 2012 and 2014. In September 2024, she gave a lecture at the Institut de sciences sociales économiques et politiques, a group founded by Marion Maréchal, a far-right political figure. Dora Moutot and Marguerite Stern were welcomed shortly after by LREM deputies Caroline Yadan and Aurore Bergé, which led to protests from two other LREM elected officials, Pierre Karleskind and Raphaël Gérard, the latter denouncing Carloine Yadan's "vocabulary which makes echo of the hateful speeches heard in Poland or Hungary". Shortly after this meeting Aurore Bergé tabled an amendment to remove language inclusive of trans men from a bill designed to enshrine access to abortion.
=== One-dimensional nanostructures === The smallest possible crystalline wires with cross-section as small as a single atom can be engineered in cylindrical confinement. Carbon nanotubes, a natural semi-1D nanostructure, can be used as a template for synthesis. Confinement provides mechanical stabilization and prevents linear atomic chains from disintegration; other structures of 1D nanowires are predicted to be mechanically stable even upon isolation from the templates.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.